European Commission approves prostate cancer treatment Erleada
Erleada (apalutamide) has been approved for non-metastatic castration-resistant prostate cancer…
Erleada (apalutamide) has been approved for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease